Cadrenal Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) on December 1, 2025, reporting events occurring on November 24, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Ponte Vedra, Florida.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Lee Scott Golden, M.D., to the Board of Directors as a Class II director. Dr. Golden was also appointed to the Science and Technology Committee. His term will expire at the 2027 annual meeting of stockholders.
Management Commentary and Compensation
Dr. Golden brings over 25 years of industry experience, most recently serving as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. His compensation package includes an annual fee of $35,000 for the fiscal year ending December 31, 2025, plus equity awards from time to time. He has also entered into a standard indemnification agreement with the Company. The filing notes no family relationships between Dr. Golden and existing directors or officers.
Investor Verification Checklist
- Verify Dr. Golden's current employment status and any potential conflicts of interest with PTC Therapeutics, Inc.
- Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Confirm the specific terms of the equity awards granted to Dr. Golden in future filings.
- Check the Company's latest 10-K or 10-Q for the most recent financial position, as this 8-K contains no financial data.